Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/05/2025
• Auteurs : Mikael CohenFabien RollotMarc DebouverieHélène ZéphirSandra VukusicJérome de SezePierre LabaugeCassandre Landes-ChâteauLydiane MondotMichael LevrautAurélie RuetEric BergerDavid LaplaudJonathan CironBertrand BourreEmmanuelle Le PageCaroline PapeixEric ThouvenotAbdullatif Al KhedrBruno StankoffJean PelletierÉlisabeth MaillartOlivier CasezThibault MoreauGilles-Louis DeferPierre ClavelouPhilippe CabreSolène MoulinJean Philippe NeauMickael ZedetKarolina HankiewiczInès DoghriHaifa Ben NasrCorinne PottierLaurent MagyDalia Dimitri BoulosOlivier HeinzlefJean-Philippe CamdessanchéMarc CoustansChantal NifleDavid BrassatRomain CaseyChristine Lebrun-Frenay
• Organismes : Hôpital Pasteur [Nice] UR2CA - URRIS - Unité de Recherche sur le syndrome Radiologique ISolé et maladies apparentées Hospices Civils de Lyon Université Claude Bernard Lyon 1 Observatoire Français de la Sclérose En Plaques [Lyon] Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Fondation Eugène Devic EDMUS Service de neurologie [CHRU Nancy] Lille Neurosciences & Cognition - U 1172 Centre Hospitalier Régional Universitaire [CHU Lille] Hospices Civils de Lyon Observatoire Français de la Sclérose En Plaques [Lyon] Université Claude Bernard Lyon 1 Fondation Eugène Devic EDMUS Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center CIC Strasbourg Hôpitaux Universitaires de Strasbourg Hôpital de Hautepierre [Strasbourg] Centre Hospitalier Régional Universitaire [Montpellier] Université de Montpellier Hôpital Pasteur [Nice] UR2CA - URRIS - Unité de Recherche sur le syndrome Radiologique ISolé et maladies apparentées Hôpital Pasteur [Nice] UR2CA - URRIS - Unité de Recherche sur le syndrome Radiologique ISolé et maladies apparentées Hôpital Pasteur [Nice] UR2CA - URRIS - Unité de Recherche sur le syndrome Radiologique ISolé et maladies apparentées Centre Hospitalier Universitaire de Bordeaux Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale Service de Neurologie [CHRU Besançon] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology CIC Plurithématique de Nantes Centre Hospitalier Universitaire de Toulouse Institut Toulousain des Maladies Infectieuses et Inflammatoires CHU Rouen Service de Neurologie [CHU Rennes] Centre d'Investigation Clinique [Rennes] Hôpital Fondation Adolphe de Rothschild = Adolphe de Rothschild Foundation Hospital Service de Neurologie [CHU Nimes] Institut de Génomique Fonctionnelle CHU Amiens-Picardie CHU Saint-Antoine [AP-HP] Hôpital de la Timone [CHU - APHM] CHU Pitié-Salpêtrière [AP-HP] CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Translational Research in Autoimmunity and Inflammation Group Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand Université de Caen Normandie CHU Caen Normandie – Centre Hospitalier Universitaire de Caen Normandie CHU Clermont-Ferrand Université Clermont Auvergne Hôpital Pierre Zobda-Quitman [CHU de la Martinique] Hôpital Maison Blanche Centre hospitalier universitaire de Poitiers = Poitiers University Hospital Hôpital Henri Mondor Centre Hospitalier Universitaire de La Réunion Centre Hospitalier Régional Universitaire de Tours Centre Hospitalier Sud Francilien - Centre Hospitalier d'Evry Hôpital NOVO Centre Hospitalier Universitaire Dupuytren 1 et 2 Hôpital Bicêtre [GHU AP-HP. Université Paris-Saclay, Le Kremlin-Bicêtre] Centre hospitalier intercommunal de Poissy/Saint-Germain-en-Laye - CHIPS [Poissy] Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Centre Hospitalier Intercommunal de Cornouaille Centre Hospitalier de Versailles André Mignot CHU Pitié-Salpêtrière [AP-HP] Université Claude Bernard Lyon 1 Hospices Civils de Lyon Observatoire Français de la Sclérose En Plaques [Lyon] Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Fondation Eugène Devic EDMUS Hôpital Pasteur [Nice] UR2CA - URRIS - Unité de Recherche sur le syndrome Radiologique ISolé et maladies apparentées
• Publié dans European Journal of Neurology le 22/10/2020

---

Résumé : Background: Real-world data suggest that the early use of highly active therapies (HAT) may reduce the risk of transition to secondary progressive MS (SPMS). However, current knowledge about predictive factors of outcomes needs to be improved. The primary objective of this study was to determine factors associated with the occurrence of SPMS in patients treated early after MS onset with an HAT. Methods: Retrospective, multicentric study based on the French MS database. Patients who initiated a HAT within 5 years after MS onset, EDSS ⩽4, and had a follow-up >5 years were included. The association of each covariate at baseline with time to the occurrence of SPMS was quantified by hazard ratios (HRs) in unadjusted and adjusted Cox proportional hazards models. Results: Two thousand two hundred and thirty-seven patients were included in the analysis: mean age 31.6 years, female/male sex ratio 2.3, and median EDSS 2.0. The estimated probability of reaching SPMS, progression independent of relapse activity (PIRA) and progression independent of activity (PIA) at 10 years was 8%, 22%, and 11%, respectively. After adjustment, we found that female patients (HR 0.64, p = 0.036) had a lower risk of developing SPMS. Older age, EDSS >0 (HR 7.44, p < 0.001), and oral versus intravenous HAT (HR 1.97, p = 0.003) were significantly associated with an increased SPMS risk. Early PIRA and PIA predicted conversion to SPMS. Conclusions: Early HAT use resulted in a low risk of developing SPMS over 10 years. Introducing the HAT before any residual disability was associated with a lower risk of progression.

---

Fichiers liés : Cohen et al 2025.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/05/2025
• Auteurs : Kien Vu TrungEinas Abou-AliAiste GullaKevin SoaresFabrice CaillolWoo PaikBertrand NapoleonAsif HalimiViliam MasarykMarco BrunoEnrique Pérez-Cuadrado-RoblesLouisa BolmSteffen SeyfriedMaria PetroneBengisu YilmazCharles VollmerArthur BergerLaura MagginoPeter SchemmerDörte WichmannElias KaramAna DugicLumir KunovskySara RegnerSébastien GaujouxMarcus HollenbachChristian HeiseFrancesco AuriemmaGalen LeungMark SchattnerWilliam JarnaginTiegong WangMarc GiovanniniJean Philippe RatoneAlessandro ZerbiGennaro NappoUrban ArneloErik HaraldssonAlexander WaldthalerUwe WillRita SaadehSophia van der WielPierre DeprezAlain SauvanetTobias KeckFrancois SoucheJean FabreNicolas MusquerGeorg KählerAlberto MarianiPiera ZaccariGiulio BelfioriMassimo FalconiStefano PartelliIhsan Ekin DemirGüralp CeyhanJean-Marc RégimbeauJohan GagniéreAlessandro RepiciAndrea AnderloniFabio CascianiMarco del ChiaroAtsushi ObaRichard SchulickRoberto SalviaAna LaranjoDiogo LibanioMadaline IlieJohanna LaukkarinenAlbrecht HoffmeisterJonas RosendahlBrigitte SchumacherLouise BarbierEphrem SalaméArnaud AlvèsNicolas RegenetSteffen MuehldorferStéphanie TruantKarel CacaMarcel TantauDavid BirnbaumJens WernerKestutis StrupasEdris WediKatrin SalzmannMatthieu BruzziRenato-Micelli LupinacciPatrice DavidLilian SchwarzArthur SchmidtTullio PiardiMartin BrunelJean-Christoph VaillantCharles de PonthaudCeline LejeuneRaffaele BrustiaRim CherifPaul-Noet DumontFrederic PratMatthias LöhrBenjamin MeierBogdan MiutescuRainer Christoph MikschYosuke InoueMario Dinis-RibeiroTobias KleemannVasile SandruReea AholaDavid AlbersTiago GonçalvesTobias WeismüllerDominik HelingThilo HackertStefano CrippaMoritz SchiemerSohei SatoiPatrick MichlSebastian Krug
• Organismes : Centre for Wireless Communications [University of Oulu] Vilnius University [Vilnius] Memorial Sloan Kettering Cancer Center Institut Paoli-Calmettes Hôpital privé Jean Mermoz [Lyon] Department of Gastroenterology and Hepatology Hôpital Européen Georges Pompidou [APHP] Kaunas University of Technology Centre Hospitalier Universitaire d'Angers Heidelberg University Hospital [Heidelberg] Chirurgie digestive [CHU Amiens] Simplification des soins chez les patients complexes - UR UPJV 7518
• Publié dans Gastrointestinal Endoscopy le 25/10/2020

---

Résumé : Background and study aims: Endoscopic papillectomy (EP) is the standard treatment for non-invasive ampullary lesions (AL), while advanced cases require surgery. Managing AL is challenging and may lead to over- or undertreatment. We developed a score to identify the best candidates for endoscopic or surgical treatment. Patients and methods: We analyzed 447 patients who underwent EP. The cohort was randomly split into a training (n=325) and validation set (n=122). Logistic regression identified predictors for incomplete resection (R1), which were incorporated into a four-item score. Performance was assessed using AUROC. Results: Independent predictors for R1 included size≥30mm(S), high-grade dysplasia/invasive cancer(D), laterally-spreading-lesion(L), and bile/pancreatic duct dilation(D). AL with 0-1 points had the highest R0 rates (training: 86.0%; validation: 88.5%), while ≥2 points significantly increased R1 rates (training: 52.0%; validation: 57.7%; p<0.001). AUROC was 0.792 (training) and 0.708 (validation). Conclusion: The SDLD score predicts incomplete resection in EP and aids treatment decisions.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/05/2025
• Auteurs : Gilbert BensimonP Nigel LeighTimothy TreeAndrea MalaspinaChristine Am PayanHang Phuong PhamPieter KlaassenPamela ShawAhmad Al KhleifatMaria-Del-Mar AmadorShahram AttarianSimon BellStéphane BeltranEmilien BernardWilliam CamuPhilippe CorciaJean-Christophe CorvolPhilippe CouratierVéronique Brunaud-DanelRabab DebsClaude DesnuelleAikaterini DimitriouJohn EalingFlorence EsselinMarie-Céline FleuryGeorge GorrieAude-Marie GrapperonAdèle HestersRaul Juntas-MoralesIvan KolevGéraldine LautretteNadine Le ForestierChristopher McdermottNicolas PageotFrançois SalachasNikhil SharmaMarie-Hélène SorianiJemeen SreedharanJuliette SvahnNick VerberAnnie VerschuerenOzlem YildizCarey SuehsSafaa Saker-DelyeClaudie MullerChristophe MasseguinHana HajduchovaJanine KirbyCecilia GarlandaMassimo LocatiHenrik ZetterbergBernard AsselainAmmar Al-Chalabi
• Organismes : BESPIM CHU Pitié-Salpêtrière [AP-HP] Sorbonne Université Brighton and Sussex Medical School King‘s College London Blizard Institute Queen Mary University of London UCL Queen Square Institute of Neurology CHU Pitié-Salpêtrière [AP-HP] Hôpital Universitaire Carémeau [Nîmes] Parean biotechnologies The Institute of Neuroscience [Sheffield] University of Sheffield [Sheffield] King‘s College London CHU Pitié-Salpêtrière [AP-HP] Centre de Référence Maladies Rares SLA Ile de France [GHU Pitié-Salpêtrière] Hôpital de la Timone [CHU - APHM] ERN EURO-NMD – European Reference Network for Rare Neuromuscular Diseases University of Sheffield [Sheffield] NHS Foundation Trust [London] Centre Hospitalier Régional Universitaire de Tours Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] Institut NeuroMyoGène - Appui à la recherche Institut des Neurosciences de Montpellier Hôpital Gui de Chauliac [CHU Montpellier] Centre Hospitalier Régional Universitaire de Tours Institut du Cerveau = Paris Brain Institute Sorbonne Université CHU Pitié-Salpêtrière [AP-HP] Centre Hospitalier Universitaire Dupuytren 1 et 2 Centre Hospitalier Régional Universitaire [CHU Lille] Centre de Référence Maladies Rares SLA Ile de France [GHU Pitié-Salpêtrière] Service de Neurologie [CHU Nice] King's College Hospital Institut des Neurosciences de Montpellier Département de Neurologie [Hôpital Gui de Chauliac - CHU Montpellier] Hôpital de Hautepierre [Strasbourg] Queen Elizabeth University Hospital (Glasgow) ERN EURO-NMD – European Reference Network for Rare Neuromuscular Diseases Hôpital de la Timone [CHU - APHM] CHU Pitié-Salpêtrière [AP-HP] Centre de Référence Maladies Rares SLA Ile de France [GHU Pitié-Salpêtrière] Vall d'Hebron University Hospital [Barcelona] Centre hospitalier de Saint-Brieuc [Hôpital Yves Le Foll] Centre Hospitalier Universitaire Dupuytren 1 et 2 Service de Neurologie [CHU Limoges] Institut du Cerveau = Paris Brain Institute University of Sheffield [Sheffield] Département de neurologie [Montpellier] CHU Pitié-Salpêtrière [AP-HP] Centre de Référence Maladies Rares SLA Ile de France [GHU Pitié-Salpêtrière] Malviya National Institute of Technology, J L N Marg, Jaipur, Rajasthan, India. Centre Hospitalier Universitaire de Nice Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] Neurologie, maladies neuro-musculaires [Hôpital de la Timone - APHM]
• Publié dans The Lancet le 02/11/2020

---

Résumé : Background: Amyotrophic lateral sclerosis (ALS) is a life-threatening disease characterised by progressive loss of motor neurons with few therapeutic options. The MIROCALS study tested the hypothesis that low-dose interleukin-2 (IL-2LD) improves survival and function in ALS. Methods: In this randomised, double-blind, placebo-controlled trial, male and female riluzole-naive participants, with either a possible, laboratory-supported probable, probable, or definite ALS diagnosis (revised El Escorial criteria), aged 18-76 years, with symptom duration of 24 months or fewer, and slow vital capacity of 70% or more, underwent a riluzole-only 12-18 week run-in period before randomisation in a 1:1 ratio to either 2 million international units (MIU) IL-2LD or placebo by subcutaneous injection daily for 5 days every 28 days over 18 months. The primary endpoint was survival at 640 days (21 months). Secondary outcomes included safety, ALS Functional Rating Scale-Revised (ALSFRS-R) score, and biomarker measurements including regulatory T-cells (Tregs), cerebrospinal fluid (CSF)-phosphorylated-neurofilament heavy-chain (CSF-pNFH), and plasma and CSF-chemokine ligand 2 (CCL2). The primary endpoint analysis used unadjusted log-rank and Cox's model adjusted analyses using pre-defined prognostic covariates to control for the disease and treatment response heterogeneity. The study was 80% powered to detect a two-fold decrease in the risk of death by the log-rank test in the intention-to-treat (ITT) population, including all randomly allocated participants. MIROCALS is registered with ClinicalTrials.gov (NCT03039673) and is complete. Findings: From June 19, 2017, to Oct 16, 2019, 304 participants were screened, of whom 220 (72%) met all criteria for random allocation after the 12-to-18-week run-in period on riluzole. 136 (62%) of participants were male and 84 participants (38%) were female. 25 (11%) of the 220 randomly allocated participants were defined as having possible ALS under El Escorial criteria. At the cutoff date there was no loss to follow-up, and all 220 patients who were randomly allocated were documented as either deceased (90 [41%]) or alive (130 [59%]), so all participants were included in the ITT and safety populations. The primary endpoint unadjusted analysis showed a non-significant 19% decrease in risk of death with IL-2LD (hazard ratio 0·81 [95% CI 0·54-1·22], p=0·33), failing to demonstrate the expected two-fold decrease in risk of death. The analysis of the primary endpoint adjusted on prognostic covariates, all measured at time of random allocation, showed a significant decrease of the risk of death with IL-2LD (0·32 [0·14-0·73], p=0·007), with a significant treatment by CSF-pNFH interaction (1·0003 [1·0001-1·0005], p=0·001). IL-2LD was safe, and significantly increased Tregs and decreased plasma-CCL2 at all timepoints. Stratification on CSF-pNFH levels measured at random allocation showed that IL-2LD was associated with a significant 48% decrease in risk of death (0·52 [0·30-0·89], p=0·016) in the 70% of the population with low (750-3700 pg/mL) CSF-pNFH levels, while in the 21% with high levels (>3700 pg/mL), there was no significant difference (1·37 [0·68-2·75], p=0·38). Interpretation: With this treatment schedule, IL-2LD resulted in a non-significant reduction in mortality in the primary unadjusted analysis. However, the difference between the results of unadjusted and adjusted analyses of the primary endpoint emphasises the importance of controlling for disease heterogeneity in ALS randomised controlled trials. The decrease in risk of death achieved by IL-2LD therapy in the trial population with low CSF-pNFH levels requires further investigation of the potential benefit of this therapy in ALS.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/05/2025
• Auteurs : Romain ManetHugues de CoursonCyrille CapelChristophe JoubertNathalie ChivoretMatthieu FaillotBaptiste BalançaAlexandre Bani-SadrMickael CardinaleAndres CocaFrançois CottonPierre EsnaultClémentine GalletSébastien GazzolaStéphane GoutagnyVincent JeckoMarion Le MarechalJacques LuautéGuillaume MortametJean-Denis MoyerHervé QuintardAlice RollandÉdouard SamarutStéphanie SigautEric VerinMathieu VinchonPhilippe DecqJean-François PayenArnaud Dagain
• Organismes : Hospices Civils de Lyon Bordeaux population health CHU Amiens-Picardie CHirurgie, IMagerie et REgénération tissulaire de l’extrémité céphalique - Caractérisation morphologique et fonctionnelle - UR UPJV 7516 Hopital d'instruction des armées Sainte-Anne [Toulon] Service de Neurologie [CHU Nice] CHU Pitié-Salpêtrière [AP-HP] Institut du Cerveau = Paris Brain Institute Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Université Claude Bernard Lyon 1 Hospices Civils de Lyon Équipe de Recherche Translationnelle et Intégrative en Épilepsie - Translational and Integrative Group in Epilepsy Research Team Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Hopital d'instruction des armées Sainte-Anne [Toulon] Centre Hospitalier Universitaire [Strasbourg] Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé Hopital d'instruction des armées Sainte-Anne [Toulon] Hospices Civils de Lyon Hopital d'instruction des armées Sainte-Anne [Toulon] Hôpital Beaujon [AP-HP] Optimisation thérapeutique en Neuropsychopharmacologie Hôpital de la Timone [CHU - APHM] Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale Biostatistique et technologies de l'information et de la communication (BioSTIC) - [Hôpital de la Timone - APHM] Hôpital Pellegrin CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Médecine Physique et Réadaptation [Hôpital Henry Gabrielle - Lyon] Équipe Évaluer, comprendre, soutenir les trajectoires motrice, perceptive et sociale - Evaluating, understanding, supporting motor, perceptive and social Trajectories Team CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Hôpital Beaujon [AP-HP] Hôpitaux Universitaires de Genève = University Hospital of Geneva [Genève] Clinique du Millénaire - Oc Santé [Montpellier] Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes-Angers Hôpital Beaujon [AP-HP] Maladies neurodéveloppementales et neurovasculaires CHU Rouen Hospices Civils de Lyon Institut de Biomécanique Humaine Georges Charpak Hôpital Beaujon [AP-HP] Université Grenoble Alpes Hopital d'instruction des armées Sainte-Anne [Toulon] École du Val de Grâce
• Publié dans Neurochirurgie le 22/10/2020

---

Résumé : Objective. To develop a multidisciplinary French framework addressing neurosurgical management in the initial phase of traumatic brain injury (TBI) in adults and children.Design. A panel of 29 experts was formed at the request of the French Society of Neurosurgery (SFNC), with the participation of the French Society of Pediatric Neurosurgery (SFNCP), French Society of Private-Practice Neurosurgeons (SFNCL), French-Speaking Neurocritical Care and Neuro-Anesthesiology Society (ANARLF), French Society of Anesthesia, Critical Care and Perioperative Medicine (SFAR), French-Speaking Pediatric Emergency and Intensive Care Group (GFRUP), French Society of Neuroradiology (SFNR), French-Speaking Infectious Diseases Society (SPILF), and the French Society of Physical Medicine and Rehabilitation (SOFMER).Methods. Questions were formulated using the PICO (Patients, Intervention, Comparison, Outcome) format, grouped into 7 categories: 1. Factors of poor prognosis, 2. Extradural hematoma, 3. Acute subdural hematoma, 4. Skull-base fracture and dural tear, 5. Penetrating traumatic brain injury, 6. Post-traumatic cerebrospinal fluid disorder, and 7. Pediatric specificities.Results. Synthesis by the experts and application of the GRADE® method resulted in the formulation of 45 recommendations. Strong consensus was reached for all recommendations at the first round of rating,Conclusion. There was a strong consensus among the experts on important interdisciplinary recommendations to improve the neurosurgical management of patients with TBI.

---

Fichiers liés : BPH_Neurochirurgie_2025_Manet.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 29/04/2025
• Auteurs : Guillaume ThirelLila ColletFabienne RoussetOlivier DelaigueDidier FrancoisJoël GailhardMatthieu Le LayCharles PerrinMathieu ReverdyRaphaëlle SamacoïtsMorgane TerrierJean-Philippe VidalJean-Pierre Wagner
• Organismes : Hydrosystèmes continentaux anthropisés : ressources, risques, restauration Centre d'études spatiales de la biosphère Hydrosystèmes continentaux anthropisés : ressources, risques, restauration Optimisation, Simulation, Risque et Statistiques pour les Marchés de l’Energie Direction de la climatologie et des services climatiques Hydrosystèmes continentaux anthropisés : ressources, risques, restauration Centre de Recherche en Géographie EDF DTG DMM EDF - Division Technique Générale Hydrosystèmes continentaux anthropisés : ressources, risques, restauration RiverLy - Fonctionnement des hydrosystèmes Direction de la climatologie et des services climatiques Hydrosystèmes continentaux anthropisés : ressources, risques, restauration Covea Tech [Paris] RiverLy - Fonctionnement des hydrosystèmes Direction Régionale de l'Environnement, de l'Aménagement et du Logement - Grand Est
• Publié dans LHB Hydroscience Journal le 09/11/2021

---

Résumé : It is essential to assess the impact of future climate change on catchment hydrology in a rigorous manner, accounting for uncertainties. In this study, we assess the impact of climate change on the natural streamflow of the French part of the Meuse catchment. Climate projections from two Representative Concentration Pathways (RCPs) and five General Circulation Model/Regional Climate Model (GCM/RCM) couples were retrieved to feed four hydrological models run with several parameter sets to assess future streamflow. A variance analysis tool was employed to partition the sources of uncertainty. Although an increase in air temperature is expected in the future, particularly with the RCP 8.5, the projected trend in precipitation remains uncertain. A slight increase in annual precipitation, an increase in winter precipitation and an uncertain signal for summer precipitation are anticipated. These developments will result in an increase in winter streamflow and an uncertain signal for summer streamflow, although these evolutions may not be homogeneous along the Meuse course. Regarding uncertainties, internal variability represents the greatest uncertainty in the near future, while climate models account for the highest uncertainty in the mid and far futures. The results were found to be comparable to those of the Francewide Explore2 project.

---

Fichiers liés : Future streamflow along the French part of the Meuse River a closer look at uncertainties.pdf

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 28/04/2025
• Auteurs : Julien RouzotEmmanuel HebrardChristian ArtiguesPhilippe GarnierPierre LopezAdrien MaillardGregg R. Rabideau
• Organismes : Équipe Recherche Opérationnelle, Optimisation Combinatoire et Contraintes Équipe Recherche Opérationnelle, Optimisation Combinatoire et Contraintes Équipe Recherche Opérationnelle, Optimisation Combinatoire et Contraintes Équipe Recherche Opérationnelle, Optimisation Combinatoire et Contraintes Équipe Recherche Opérationnelle, Optimisation Combinatoire et Contraintes ISAE-SUPAERO, Université de Toulouse Jet Propulsion Laboratory

---

Résumé : In the context of space missions, an efficient data transfer strategy is crucial to avoid onboard buffer overflow. In many missions, such as the ESA's Rosetta mission, the data produced by each instrument is temporarily stored in a dedicated buffer and then dumped to Earth during downlink windows under a limited bandwidth. Previous work has considered the overlapping Memory Dumping Problem (oMDP), which consists in assigning transfer priorities to the memory buffers and minimize the peaks memory usage. The oMDP is NP-hard and has been tackled using heuristic methods that demonstrated their efficiency on real instances. In this paper, we consider additional decisions in the memory dumping plans that are implementable in practice: data transfer from each buffer can be interrupted after a given time, once per downlink window, preventing it from dumping data until the next window. The new problem is called oMDPi (oMDP with interruptions). We obtain several structural properties and complexity results, showing in particular that oMDPi is NP-hard for at least two windows. While the complexity status of the single window oMDPi remains open, we propose a polynomial-time heuristic to solve it. We propose a hybrid heuristic to solve the general oMDPi, embedding a flow relaxation and the single window heuristic. The results on both real and realistic generated instances show that our heuristic achieves a significant reduction of memory peaks in a reasonable time compared to previous works, making the new policy attractive for future space missions.

---

Fichiers liés : IWPSS_2025.pdf

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 27/04/2025
• Auteurs : Dunya AlraddawiPhilippe KeckhutFlorian MandijaGuillaume PayenJean Charles DupontChristophe PietrasAbdanour IrbahAlain SarkissianAlain HauchecorneJacques Porteneuve
• Organismes : ATMOSPHERE - LATMOS ATMOSPHERE - LATMOS ATMOSPHERE - LATMOS Laboratoire de l'Atmosphère et des Cyclones Institut Pierre-Simon-Laplace Laboratoire de Météorologie Dynamique (UMR 8539) ATMOSPHERE - LATMOS ATMOSPHERE - LATMOS ATMOSPHERE - LATMOS Gordien Strato

---

Résumé : Water vapor information in the upper troposphere (UT) is crucial for understanding the thermodynamic conditions leading to the formation of cirrus clouds and persistent contrails. Both phenomena significantly contribute to aviation-induced radiative forcing, driving global mitigation efforts. Raman lidars provide high-resolution humidity profiles, describing altitudes prone to ice supersaturation—conditions that are challenging to detect and accurately represent in current models.In this study, Raman lidar Water Vapor Mixing Ratio (WVMR) measurements from various sites in France were used to evaluate the performance of the ERA5 model in assessing humidity at typical aircraft altitudes. Additionally, the uncertainties in Microwave Limb Sounder (MLS) WVMR measurements at the same altitudes were assessed. Raman lidar profiles were aggregated into pseudo-monthly datasets to facilitate comparison with the limited number of MLS overpasses at each site, enabling validation of spatio-temporal pseudo-monthly lidar-matched MLS and ERA5 WVMR profiles.The MLS dataset offers one of the longest records of WVMR, making it a valuable resource for trend assessment. This investigation enables the validated use of these datasets for studying UT humidity trends and variability on seasonal and annual scales over the past decade.

---

Source

---

• Type de publi. :
• Date de publi. : 27/04/2025
• Auteurs : Aubin CourtyPatrick StellaRachna BhoonahDidier HebertPhilippe LaguionieDenis MaroPierre RouspardEric LamaudDenis QueloErwan PersonneSébastien Saint-Jean
• Organismes : Ecologie fonctionnelle et écotoxicologie des agroécosystèmes Ecologie fonctionnelle et écotoxicologie des agroécosystèmes Ecologie fonctionnelle et écotoxicologie des agroécosystèmes Laboratoire expérimental de recherche et d’expertise sur les transferts des radionucléides dans le milieu atmosphérique Laboratoire expérimental de recherche et d’expertise sur les transferts des radionucléides dans le milieu atmosphérique Laboratoire expérimental de recherche et d’expertise sur les transferts des radionucléides dans le milieu atmosphérique Laboratoire expérimental de recherche et d’expertise sur les transferts des radionucléides dans le milieu atmosphérique Interactions Sol Plante Atmosphère Laboratoire expérimental de recherche et d’expertise sur les transferts des radionucléides dans le milieu atmosphérique Ecologie fonctionnelle et écotoxicologie des agroécosystèmes Ecologie fonctionnelle et écotoxicologie des agroécosystèmes

---

Résumé : According to the Global Burden of Diseases, PM2.5 (particles with a diameter under 2.5 µm) is the leading cause of diseases and deaths in 2021 (Brauer et al., 2024). Along with decreased emissions, removal through deposition is used to reduce exposure to particulate matter (PM). With a leaf area index (m² of leaf per m² of land) usually higher than 1, plants allow for a higher deposition surface, hence more particle removal from ambient air. Thus, understanding and estimating PM deposition on vegetation is necessary to assess the impact of vegetation on air quality. In situ measurements above vegetation have shown that PM (vertical) deposition velocity can be positive and negative (Pellerin et al., 2017). No 1-dimensional PM deposition model can predict such values. The objective of this study is to implement a working bi-directional PM exchange scheme in the Surfatm exchange model (Personne et al., 2024), a 1-dimensional SVAT model, using a resistive scheme. The bi-directional fluxes are introduced using a compensation point approach, which can be interpreted as the PM surface concentration. This allows the concentration gradient to change signs depending on the difference of concentration between ambient air and the surface. Two PM exchange datasets above a grassland in Lusignan (France) are used to calibrate and validate the model respectively (Pellerin et al., 2017). The Surfatm-PM model can predict positive and negative deposition velocities, with notable differences attributable to the formation mechanism of the particles, such as the process of coagulation or nucleation or condensation between ambient air and (vegetated) interfaces.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 27/04/2025
• Auteurs : Pierre VeraPhilippe GiraudSébastien HapdeyPierrick GouelOrianne JanPaul Le RouxAlexandra LanglaisFlorence Le TinierAnaïs OlivierEtienne MartinAlina Berriolo-RiedingerNicolas PourelJean Marc BrogliaPierre BoisselierSophie GuillemardNaji SalemIsabelle Brenot-RossiCamilo GarciaCéline BertholdEtienne Giroux-LeprieurDamien MoreauSophie GuillermKhadija BenaliLaurent TessonnierClarisse Audigier-ValetteDelphine LerougeElske QuakCarole MassabeauFrédéric CourbonMaxime LooAnne LarrouyNadia GhazzarPhilippe Chaumet-RiffaudElodie AmourGérard ZalcmanRomain ModzelewskiSébastien Thureau
• Organismes : Analyse intégrée multimodale en santé Equipe Quantification en Imagerie Fonctionnelle Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen Analyse intégrée multimodale en santé Equipe Quantification en Imagerie Fonctionnelle Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen Analyse intégrée multimodale en santé Equipe Quantification en Imagerie Fonctionnelle Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen Analyse intégrée multimodale en santé Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen Analyse intégrée multimodale en santé Equipe Quantification en Imagerie Fonctionnelle Analyse intégrée multimodale en santé Equipe Quantification en Imagerie Fonctionnelle Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen
• Publié dans Journal of Nuclear Medicine le 26/10/2020

---

Résumé : The purpose of this study was to assess the prognostic value of 18F-FDG PET parameter variation between baseline and 42 Gy (PET2) of radiochemotherapy at 6 mo and 1 y of evaluation in patients with stage III inoperable nonsmall cell lung cancer based on RECIST 1.1. Methods: In total, 158 patients in a prospective multicenter phase II/III study were analyzed. Patients were randomized into 2 groups: an experimental arm (group A) and a standard arm (group B). Patients from group A with residual metabolism on PET2 (group A+) at 42 Gy received a radiation boost (74 Gy). Patients without residual uptake on 18F-FDG PET at 42 Gy (group A-) and patients in group B received a standard radiotherapy dose (66 Gy). We compared group A with group B. The 18F-FDG PET parameters SUVmax, SUVmean, SUVpeak, peak SUV normalized on lean body mass, mean SUV normalized on lean body mass, total lesion glycolysis, total metabolic tumor volume (MTV) (tumor and nodes), and tumor MTV were measured. All patients were evaluated with RECIST 1.1 using CT at 6 mo and 1 y after radiochemotherapy. Progression-free survival and overall survival were evaluated. Results: Except for the radiotherapy dose (P < 0.001), patient demographic characteristics were similar between the 2 groups (A vs. B). All 18F-FDG PET uptake and volume parameter measurements were correlated. Therefore, only the change in SUVmax (ΔSUVmax) and total MTV were selected for the analysis. There was no significant difference in any variable between the 2 groups. In the multivariate analysis, ΔSUVmax appeared to be the most important prognostic factor for overall survival, and SUVmax of PET2 appeared to be the most important prognostic factor for progression-free survival. Conclusion: 18F-FDG PET at 42 Gy can be used to identify good responders to radiochemotherapy in patients with inoperable stage III nonsmall cell lung cancer. The SUVmax of PET2 and ΔSUVmax are independent prognostic factors.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 24/04/2025
• Auteurs : David M SmadjaClément R MassonnaudAurélien PhilippeMickael RosaSophie LuneauAntoine RauchNathan Peiffer-SmadjaAmandine Gagneux-BrunonJulien PoissyMaxime GruestAlexandre UngValérie PourcherFrançois RaffiLionel PirothHélène EsperouChristelle DelmasDrifa BelhadiAlpha DialloJuliette SaillardAline DechanetNoémie MercierAxelle DupontFrançois-Xavier LescureFrançois GoehringerStéphane JaureguiberryFrançois DanionViolaine TolsmaAndré CabieJohan CourjonSylvie LeroyJoy MootienBruno MourvillierSébastien GallienJ.P. LanoixElisabeth Botelho-NeversFlorent WalletJean-Christophe RichardJean ReuterAlexandre GaymardRichard GreilGuillaume Martin-BlondelClaire AndréjakYazdan YazdanpanahCharles BurdetJean-Luc DiehlMaya HitesFlorence AderSophie SusenFrance MentréAnnabelle DupontSandrine Couffin-CadièrguesHélène EsperouBernd LamprechtMichael JoannidisAlexander EgleRichard GreilAntoine AltdorferVincent FraipontLeila BelkhirMaya HitesGil VerscheldenViolaine TolsmaDavid BougonAgathe DelboveMarie GousseffNadia SaidaniGuilhem WattecampsFélix DjossouLoïc EpelboinPierre-Alexandre RogerYoann ZerbibKevin BouillerCatherine ChirouzeJean-Christophe NavellouAlexandre BoyerCharles CazanaveAlexandre DuvignaudDidier GrusonDenis MalvyHenry LessireMartin MartinotPascal AndreuMathieu BlotLionel PirothJean Pierre QuenotOlivier EpaulardNicolas TerziKarine FaureEmmanuel FaureJulien PoissySaad NseirFlorence AderLaurent ArgaudTristan FerryThomas PerpointVincent PiriouJean-Christophe RichardJulien TextorisFlorent ValourFlorent WalletAndré CabiéJean-Marie TurmelCyrille ChabartierRostane GaciCéline RobertAlain MakinsonVincent Le MoingKada KloucheOlivier HinschbergerJoy MootienSébastien GibotFrançois GoehringerAntoine KimmounBenjamin LefevreDavid BoutoilleEmmanuel CanetBenjamin GaboritPaul Le TurnierFrançois RaffiJean ReignierJohan CourjonJean DellamonicaSylvie LeroyCharles-Hugo MarquettePaul LoubetClaire RogerAlbert SottoCédric BruelBenoît PilmisGuillaume GeriElisabeth RouveixOlivier BouchaudSamy FigueiredoStéphane JaureguiberryXavier MonnetLila BouadmaFrançois-Xavier LescureNathan Peiffer-SmadjaJean-François TimsitYazdan YazdanpanahSolen KernéisMarie LachâtreOdile LaunayJean-Paul MiraJulien MayauxValérie PourcherJérôme AboabFlora CrockettNaomi SayreClément DubostCécile FickoDavid LebeauxSébastien GallienArmand Mekontso-DessapJérôme Le PavecFrancois StefanHafid Ait-OufellaKarine LacombeJean-Michel MolinaMurielle FartoukhGilles PialouxFirouzé Bani-SadrBruno MourvillierFrançois BenezitFabrice LaineBruno LaviolleYves Le TulzoMatthieu RevestElisabeth Botelho-NeversAmandine Gagneux-BrunonGuillaume ThieryFrançois DanionYves HansmannFerhat MezianiWalid OulehriCharles TacquardFanny Bounes-VardonGuillaume Martin-BlondelMarlène Murris-EspinBéatrice Riu-PoulencVanessa JeanmichelEric SennevilleLouis BernardDenis GarotJean ReuterThérèse StaubMarc BernaSandra BrazJoao Miguel Ferreira RibeiroJosé-Artur PaivaRoberto Roncon-AlbuquerqueBenjamin Leveau
• Organismes : Hôpital Européen Georges Pompidou [APHP] Infection, Anti-microbiens, Modélisation, Evolution AP-HP - Hôpital Bichat - Claude Bernard [Paris] Hôpital Européen Georges Pompidou [APHP] Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011 Hôpital Européen Georges Pompidou [APHP] Centre Hospitalier Régional Universitaire [CHU Lille] AP-HP - Hôpital Bichat - Claude Bernard [Paris] Centre International de Recherche en Infectiologie Centre d'Investigation Clinique - Epidémiologie Clinique [CHU Saint-Etienne] coVAPid Study Group Hôpital Européen Georges Pompidou [APHP] Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011 Institut Pierre Louis d'Epidémiologie et de Santé Publique Centre d'Investigation Clinique 1432 (Dijon) - Epidemiologie Clinique/Essais Cliniques Institut de Santé Publique Institut de Santé Publique Infection, Anti-microbiens, Modélisation, Evolution Département d'épidémiologie, biostatistique et recherche clinique Agence Nationale de Recherches sur le Sida et les Hépatites Virales Agence Nationale de Recherches sur le Sida et les Hépatites Virales AP-HP - Hôpital Bichat - Claude Bernard [Paris] ANRS - Maladies infectieuses émergentes AP-HP - Hôpital Bichat - Claude Bernard [Paris] Infection, Anti-microbiens, Modélisation, Evolution AP-HP - Hôpital Bichat - Claude Bernard [Paris] Service d'Evaluation et Information Médicales [CHRU Nancy] Hôpital Bicêtre [GHU AP-HP. Université Paris-Saclay, Le Kremlin-Bicêtre] Hôpitaux Universitaires de Strasbourg Centre Hospitalier d'Annecy Genevois Pathogenesis and Control of Chronic and Emerging Infections Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique] Centre Hospitalier Universitaire de Nice Centre Hospitalier Universitaire de Nice Groupe hospitalier de la région de Mulhouse et Sud-Alsace Hôpital universitaire Robert Debré [Reims] Hôpital Henri Mondor CHU Amiens-Picardie Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Hospices Civils de Lyon Hospices Civils de Lyon Centre Hospitalier de Luxembourg [Luxembourg] Université Claude Bernard Lyon 1 Paracelsus Medizinische Privatuniversität = Paracelsus Medical University Unité de Pharmacoépidémiologie [CHU Toulouse] Pneumologie [CHU Amiens] Agents infectieux, résistance et chimiothérapie - UR UPJV 4294 Infection, Anti-microbiens, Modélisation, Evolution Infection, Anti-microbiens, Modélisation, Evolution Hôpital Européen Georges Pompidou [APHP] Hospices Civils de Lyon Institut Pasteur de Lille AP-HP - Hôpital Bichat - Claude Bernard [Paris] AP-HP - Hôpital Bichat - Claude Bernard [Paris] UFR de Médecine - Université de Picardie Jules Verne Médecine Intensive-Réanimation [CHU Amiens] Laboratoire Chrono-environnement (UMR 6249) Research on Healthcare Performance Institut Toulousain des Maladies Infectieuses et Inflammatoires
• Publié dans Scientific Reports le 26/10/2020

---

Résumé : We investigated whether baseline levels of biomarkers related to endotheliopathy, thromboinflammation, and fibrosis were associated with clinical outcomes in hospitalized COVID-19 patients. We analyzed the associations between baseline levels of 21 biomarkers and time to hospital discharge and change in NEWS-2 score in patients from DisCoVeRy trial. We fitted multivariate models adjusted for baseline ISARIC 4C score, disease severity, D-dimer values, and treatment regimen. Between March 22 and June 29, 2020, 603 participants were randomized; 454 had a sample collected at baseline and analyzed. The backward selection of multivariate models showed that higher baseline levels of soluble suppressor of tumorigenicity 2 (sST2) and nucleosomes were statistically associated with a lower chance of hospital discharge before day 29 (sST2: aHR 0.24, 95% CI [0.15-0.38], p < 10-9; nucleosomes: aHR 0.62, 95% CI [0.48-0.81], p < 10-3). Likewise, higher levels of baseline sST2 were statistically associated with lower changes in the NEWS-2 score between baseline and day 15 (adjusted beta 4.47, 95% CI [2.65-6.28], p < 10-5). Moreover, we evaluated sST2 involvement in a confirmation cohort (SARCODO study, 103 patients) and found that elevated baseline sST2 levels were significantly associated with lower rates of hospital discharge before day 29 and a higher model performance (AUC at day 29 of 92%) compared to models without sST2. sST2 emerged as an independent predictor of clinical outcomes in two large cohort of hospitalized COVID-19 patients, warranting further investigation to elucidate its role in disease progression and potential as a therapeutic target.

---

Source